Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
When to stop immunotherapy for advanced melanoma: the emulated target trials.
Amiot M, Mortier L, Dalle S, Dereure O, Dalac S, Dutriaux C, Leccia MT, Maubec E, Arnault JP, Brunet-Possenti F, De Quatrebarbes J, Granel-Brocard F, Gaudy-Marqueste C, Pages C, Stoebner PE, Saiag P, Lesimple T, Dupuy A, Legoupil D, Montaudié H, Oriano B, Lebbe C, Porcher R. Amiot M, et al. Among authors: mortier l. EClinicalMedicine. 2024 Dec 4;78:102960. doi: 10.1016/j.eclinm.2024.102960. eCollection 2024 Dec. EClinicalMedicine. 2024. PMID: 39717261 Free PMC article.
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.
Bozonnat A, Beylot-Barry M, Dereure O, D'Incan M, Quereux G, Guenova E, Perier-Muzet M, Dalle S, Grange F, Viguier MA, Ram-Wolff C, Feldmeyer L, Beltraminelli H, Bonnet N, Amatore F, Maubec E, Franck N, Machet L, Chasset F, Brunet-Possenti F, Bouaziz JD, Battistella M, Donzel M, Pham-Ledard A, Bejar C, Moins-Teisserenc H, Mourah S, Saiag P, Hainaut E, Michel C, Bens G, Adamski H, Aubin F, Boulinguez S, Joly P, Tedbirt B, Templier I, Troin L, Montaudié H, Ingen-Housz-Oro S, Faiz S, Mortier L, Dobos G, Bagot M, Resche-Rigon M, Montlahuc C, Serret-Larmande A, de Masson A; Cutaneous Lymphomas French Study Group. Bozonnat A, et al. Among authors: mortier l. EClinicalMedicine. 2024 Jun 21;73:102679. doi: 10.1016/j.eclinm.2024.102679. eCollection 2024 Jul. EClinicalMedicine. 2024. PMID: 39007062 Free PMC article.
Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort.
Macaire C, Lefevre W, Dalac S, Montaudié H, Legoupil D, Dereure O, Dutriaux C, Leccia MT, Aubin F, Grob JJ, Saiag P, De Quatrebarbes J, Maubec E, Lesimple T, Granel-Brocard F, Mortier L, Dalle S, Lebbé C, Prod'homme C. Macaire C, et al. Among authors: mortier l. Melanoma Res. 2025 Feb 1;35(1):50-59. doi: 10.1097/CMR.0000000000000973. Epub 2024 Nov 11. Melanoma Res. 2025. PMID: 39527777 Free PMC article.
Erratum: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.
Bozonnat A, Beylot-Barry M, Dereure O, D'Incan M, Quereux G, Guenova E, Perier-Muzet M, Dalle S, Grange F, Viguier MA, Ram-Wolff C, Feldmeyer L, Beltraminelli H, Bonnet N, Amatore F, Maubec E, Franck N, Machet L, Chasset F, Brunet-Possenti F, Bouaziz JD, Battistella M, Donzel M, Pham-Ledard A, Bejar C, Moins-Teisserenc H, Mourah S, Saiag P, Hainaut E, Michel C, Bens G, Adamski H, Aubin F, Boulinguez S, Joly P, Tedbirt B, Templier I, Troin L, Montaudié H, Ingen-Housz-Oro S, Faiz S, Mortier L, Dobos G, Bagot M, Resche-Rigon M, Montlahuc C, Serret-Larmande A, de Masson A; Cutaneous Lymphomas French Study Group. Bozonnat A, et al. Among authors: mortier l. EClinicalMedicine. 2024 Dec 6;79:102979. doi: 10.1016/j.eclinm.2024.102979. eCollection 2025 Jan. EClinicalMedicine. 2024. PMID: 39720605 Free PMC article.
Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée).
Rousset P, Nardin C, Maubec E, Heidelberger V, Picard A, Troin L, Gerard E, Kramkimel N, Steff-Naud M, Quéreux G, Gaudy-Marqueste C, Lesage C, Mignard C, Jeudy G, Jouary T, Saint-Jean M, Baroudjian B, Archier E, Mortier L, Lebbe C, Montaudié H. Rousset P, et al. Among authors: mortier l. Oncologist. 2024 Oct 3;29(10):e1364-e1372. doi: 10.1093/oncolo/oyae145. Oncologist. 2024. PMID: 38956747 Free PMC article.
Effectiveness, safety and reasons for discontinuation of sonidegib for patients with locally advanced basal cell carcinoma: A real-word evidence analysis from the French national registry CARADERM.
Basset-Seguin N, Djermane M, Herms F, Dalac S, Dereure O, Beylot-Barry M, Amini-Adle M, Minart B, Granel-Brocard F, Meyer N, Jouary T, Dreno B, Mortier L; Caraderm investigators. Basset-Seguin N, et al. Among authors: mortier l. J Eur Acad Dermatol Venereol. 2024 Dec 16. doi: 10.1111/jdv.20496. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39676714 No abstract available.
Pustular mycosis fungoides has a poor outcome: a multicentric clinicopathological and molecular case series.
Bontoux C, Badrignans M, Afach S, Sbidian E, Mboumba DL, Ingen-Housz-Oro S, Claudel A, Aubriot-Lorton MH, Chong-Si-Tsaon A, Le Masson G, Attencourt C, Dubois R, Beltzung F, Koubaa W, Beltraminelli H, Cardot-Leccia N, Balme B, Nguyen AT, Bagny K, Legoupil D, Moustaghfir I, Denamps J, Mortier L, Hammami-Ghorbel H, Skrek S, Rafaa M, Fougerousse AC, Deschamps T, Dalle S, D'incan M, Chaby G, Beylot-Barry M, Dalac S, Ortonne N. Bontoux C, et al. Among authors: mortier l. Br J Dermatol. 2024 Dec 23;192(1):125-134. doi: 10.1093/bjd/ljae312. Br J Dermatol. 2024. PMID: 39133548
First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
D'Angelo SP, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Prinzi N, Hanna GJ, Hassel JC, Kiecker F, von Heydebreck A, Güzel G, Nghiem P. D'Angelo SP, et al. Among authors: mortier l. ESMO Open. 2024 May;9(5):103461. doi: 10.1016/j.esmoop.2024.103461. Epub 2024 May 13. ESMO Open. 2024. PMID: 38744102 Free PMC article. Clinical Trial.
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.
Mortier L, Villabona L, Lawrence B, Arance A, Butler MO, Beylot-Barry M, Saiag P, Samimi M, Ascierto PA, Spada F, De Pontville M, Maio M, Berrocal A, Espinosa E, Capdevila J, Levin M, Das D, Krepler C, Grebennik D, Chiarion-Sileni V. Mortier L, et al. Am J Clin Dermatol. 2024 Nov;25(6):987-996. doi: 10.1007/s40257-024-00885-w. Epub 2024 Oct 8. Am J Clin Dermatol. 2024. PMID: 39377880 Free PMC article. Clinical Trial.
321 results